Get Premium to unlock powerful stock data

Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021

Author's Avatar
PRNewswire
Feb 24, 2021
Article's Main Image

PR Newswire

NEW HAVEN, Conn., Feb. 23, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will host a conference call and webcast to report fourth quarter and full year 2020 financial results and provide a review of recent accomplishments and anticipated upcoming milestones, on Monday March 1, 2021 at 8:30 a.m. ET.

Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg

To access the call, please dial 877-407-9120 (domestic) or 412-902-1009 (international). The conference call webcast and accompanying slide presentation can be accessed through the "Investors" section of Biohaven's website at www.biohavenpharma.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the call will be made available for two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (domestic) or 201-612-7415 (international) with conference ID 13715754. An archived webcast will be available on Biohaven's website.

About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC® ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, and spinocerebellar ataxia; and myeloperoxidase (MPO) inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.

NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC.

Biohaven Contact:
Dr. Vlad Coric
Chief Executive Officer
[email protected]

favicon.png?sn=NE89120&sd=2021-02-23 View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-to-report-fourth-quarter-and-full-year-2020-financial-results-and-recent-business-developments-on-march-1-2021-301234050.html

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

rt.gif?NewsItemId=NE89120&Transmission_Id=202102231840PR_NEWS_USPR_____NE89120&DateId=20210223
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
Rating:
0 / 5 (0 votes)

Please Login to leave a comment